<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=5.0">
    <title>ç§‘ç ”æ—¥æŠ¥ - 2025-11-05</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, "Noto Sans", sans-serif, "Apple Color Emoji", "Segoe UI Emoji";
            line-height: 1.8;
            color: #2c3e50;
            background: linear-gradient(135deg, #f5f7fa 0%, #c3cfe2 100%);
            padding: 15px;
            font-size: 16px;
        }

        .container {
            max-width: 900px;
            margin: 0 auto;
            background: white;
            padding: 35px;
            border-radius: 16px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.1);
        }

        /* æ ‡é¢˜ä¼˜åŒ– */
        h1 {
            color: #1a202c;
            font-size: 2em;
            border-bottom: 4px solid #667eea;
            padding-bottom: 15px;
            margin-bottom: 25px;
            font-weight: 700;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }

        h2 {
            color: #2d3748;
            font-size: 1.5em;
            margin-top: 40px;
            margin-bottom: 20px;
            padding-left: 15px;
            border-left: 5px solid #667eea;
            font-weight: 600;
        }

        h3 {
            color: #4a5568;
            font-size: 1.25em;
            margin-top: 28px;
            margin-bottom: 14px;
            font-weight: 600;
        }

        /* åˆ†ç±»æµè§ˆæŠ˜å åŠŸèƒ½ */
        details {
            margin: 20px 0;
            border-radius: 8px;
            overflow: hidden;
        }

        details summary {
            cursor: pointer;
            padding: 15px 20px;
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            color: #2d3748;
            font-size: 1.25em;
            font-weight: 600;
            text-align: right;
            direction: rtl;
            border-right: 5px solid #667eea;
            transition: all 0.3s ease;
            list-style: none;
            user-select: none;
        }

        details summary * {
            direction: ltr;
        }

        details summary::-webkit-details-marker {
            display: none;
        }

        details summary::before {
            content: 'â–¶';
            display: inline-block;
            margin-left: 10px;
            transition: transform 0.3s ease;
            font-size: 0.8em;
        }

        details[open] summary::before {
            transform: rotate(90deg);
        }

        details summary:hover {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            box-shadow: 0 4px 12px rgba(102, 126, 234, 0.3);
        }

        details[open] summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            border-right-color: white;
        }

        details .details-content {
            padding: 20px;
            background: white;
            border: 1px solid #e9ecef;
            border-top: none;
        }

        h4 {
            color: #718096;
            font-size: 1.1em;
            margin-top: 22px;
            margin-bottom: 12px;
            font-weight: 600;
        }

        p {
            margin-bottom: 16px;
            line-height: 1.8;
        }

        blockquote {
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            border-left: 4px solid #667eea;
            padding: 18px 22px;
            margin: 22px 0;
            border-radius: 8px;
            color: #4a5568;
            font-size: 0.95em;
            box-shadow: 0 2px 8px rgba(0,0,0,0.05);
        }

        blockquote p {
            margin-bottom: 8px;
        }

        blockquote p:last-child {
            margin-bottom: 0;
        }

        blockquote em {
            font-style: normal;
            color: #718096;
            font-size: 0.9em;
        }

        blockquote a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        blockquote a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* é¡¶éƒ¨ç½²åï¼ˆå±…å³ï¼‰ */
        .powered-by-top {
            text-align: right;
            font-size: 0.85em;
            color: #718096;
            font-style: italic;
            margin: 12px 0;
            padding-right: 5px;
        }

        .powered-by-top a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        .powered-by-top a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* AI æ€»ç»“åŒºåŸŸä¼˜åŒ– */
        .ai-summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 28px;
            border-radius: 16px;
            margin: 30px 0;
            box-shadow: 0 12px 35px rgba(102, 126, 234, 0.35);
            position: relative;
            overflow: hidden;
        }

        .ai-summary::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -50%;
            width: 200%;
            height: 200%;
            background: radial-gradient(circle, rgba(255,255,255,0.1) 0%, transparent 70%);
            pointer-events: none;
        }

        .ai-summary h2 {
            color: white;
            border-left: none;
            border-right: none;
            margin-top: 0;
            margin-bottom: 18px;
            padding-left: 15px;
            padding-right: 0;
            text-align: left;
            direction: ltr;
        }

        .ai-summary h3 {
            color: #f0f0f0;
            margin-top: 18px;
            border-right: 3px solid rgba(255,255,255,0.5);
            padding-right: 12px;
            padding-left: 0;
            text-align: right;
            direction: rtl;
        }

        .ai-summary h3 * {
            direction: ltr;
        }

        .ai-summary blockquote {
            background: rgba(255,255,255,0.15);
            border-left-color: white;
            color: white;
            backdrop-filter: blur(10px);
        }

        .ai-summary p {
            color: white;
        }

        .ai-summary strong {
            color: #fff;
            font-weight: 600;
        }

        ul, ol {
            margin-left: 28px;
            margin-bottom: 18px;
        }

        li {
            margin-bottom: 12px;
            line-height: 1.8;
        }

        /* é“¾æ¥ä¼˜åŒ– */
        a {
            color: #667eea;
            text-decoration: none;
            border-bottom: 1px solid transparent;
            transition: all 0.3s ease;
            font-weight: 500;
        }

        a:hover {
            border-bottom-color: #667eea;
            color: #764ba2;
        }

        /* è¡¨æ ¼ä¼˜åŒ– */
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            box-shadow: 0 2px 12px rgba(0,0,0,0.08);
            border-radius: 10px;
            overflow: hidden;
        }

        th, td {
            border: 1px solid #e2e8f0;
            padding: 14px 18px;
            text-align: left;
        }

        th {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            font-weight: 600;
            font-size: 0.95em;
        }

        tr:nth-child(even) {
            background: #f8f9fa;
        }

        tr:hover {
            background: #e9ecef;
            transition: background 0.3s ease;
        }

        /* å…³é”®è¯ç»Ÿè®¡è¡¨æ ¼ç‰¹æ®Šæ ·å¼ï¼ˆæ›´ç´§å‡‘ï¼‰ */
        .keywords-table {
            font-size: 0.9em;
            max-width: 600px;
        }

        .keywords-table th,
        .keywords-table td {
            padding: 10px 14px;
        }

        .keywords-table th {
            font-size: 0.9em;
        }

        hr {
            border: none;
            border-top: 2px solid #e2e8f0;
            margin: 40px 0;
        }

        strong {
            color: #2d3748;
            font-weight: 600;
        }

        code {
            background: #f1f5f9;
            padding: 3px 8px;
            border-radius: 5px;
            font-family: "SF Mono", Monaco, Consolas, "Courier New", monospace;
            font-size: 0.9em;
            color: #e53e3e;
        }

        /* ç¾åŒ–æ»šåŠ¨æ¡ */
        ::-webkit-scrollbar {
            width: 8px;
            height: 8px;
        }

        ::-webkit-scrollbar-track {
            background: #f1f1f1;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb {
            background: #667eea;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb:hover {
            background: #764ba2;
        }

        /* ç§»åŠ¨ç«¯ä¼˜åŒ– */
        @media (max-width: 768px) {
            body {
                padding: 8px;
                font-size: 15px;
            }

            .container {
                padding: 22px 18px;
                border-radius: 12px;
            }

            h1 {
                font-size: 1.6em;
                padding-bottom: 12px;
                margin-bottom: 20px;
            }

            h2 {
                font-size: 1.3em;
                margin-top: 30px;
                padding-left: 12px;
            }

            h3 {
                font-size: 1.15em;
            }

            h4 {
                font-size: 1.05em;
            }

            blockquote {
                padding: 14px 16px;
                margin: 18px 0;
            }

            .ai-summary {
                padding: 20px;
                margin: 22px 0;
            }

            .ai-summary-header {
                flex-direction: column;
                align-items: flex-start;
            }

            .powered-by {
                margin-left: 0;
                margin-top: 8px;
            }

            table {
                font-size: 0.85em;
            }

            th, td {
                padding: 10px 12px;
            }

            .keywords-table {
                font-size: 0.8em;
            }

            .keywords-table th,
            .keywords-table td {
                padding: 8px 10px;
            }

            ul, ol {
                margin-left: 22px;
            }
        }

        /* è¶…å°å±å¹• */
        @media (max-width: 480px) {
            body {
                font-size: 14px;
                padding: 5px;
            }

            .container {
                padding: 18px 14px;
            }

            h1 {
                font-size: 1.4em;
            }

            h2 {
                font-size: 1.2em;
            }

            .ai-summary {
                padding: 16px;
            }

            .powered-by {
                font-size: 0.7em;
            }
        }

        /* å¹³æ»‘æ»šåŠ¨ */
        html {
            scroll-behavior: smooth;
        }

        /* æé«˜å¯ç‚¹å‡»åŒºåŸŸ */
        @media (pointer: coarse) {
            a {
                padding: 4px 0;
                display: inline-block;
            }
        }

        /* æ‰“å°ä¼˜åŒ– */
        @media print {
            body {
                background: white;
                padding: 0;
            }

            .container {
                box-shadow: none;
                max-width: 100%;
            }

            .ai-summary {
                background: #f5f5f5;
                color: black;
                box-shadow: none;
            }

            .ai-summary h2,
            .ai-summary h3,
            .ai-summary p,
            .ai-summary strong {
                color: black;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <h1>ğŸ“… Daily Report - 2025-11-05</h1>
<blockquote>
<p>ä»Šæ—¥ç­›é€‰å‡º <strong>92</strong> æ¡å†…å®¹ï¼Œæ¥è‡ª <strong>5</strong> ä¸ªæ¥æº</p>
</blockquote>
<div class="powered-by-top">Powered by <a href="https://kyplus.de" target="_blank" rel="noopener noreferrer">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai" target="_blank" rel="noopener noreferrer">Claude</a></div>

<hr />
<div class="ai-summary">
                <h2>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</h2>
                <h3>ğŸ“° å…¬ä¼—å·</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
ç©ºé—´å¤šç»„å­¦æ™ºèƒ½æ•´åˆä¸è°ƒæ§ç½‘ç»œæ¨æ–­ï¼ˆ1ï¼‰ä¸ºå¥åº·æˆå¹´äººå…ç–«è€åŒ–ç ”ç©¶æä¾›å…¨æ™¯å›¾ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- ç»†èƒè¡°è€åœ¨éè‚¿ç˜¤ç–¾ç—…ä¸­çš„ç‰¹å¾ç ”ç©¶ï¼ˆ2, 3, 7ï¼‰ã€‚<br />
- åŸºäºå•ç»†èƒã€å…¨è½¬å½•ç»„åŠç©ºé—´è½¬å½•ç»„æŠ€æœ¯ï¼Œç»“åˆæœºå™¨å­¦ä¹ è¿›è¡Œè‚¿ç˜¤å…ç–«ã€ç»†èƒé€šè®¯åŠCAFè¡°è€è¡¨å‹ç ”ç©¶ï¼ˆ1, 4, 5, 6, 7, 8, 9, 13ï¼‰ã€‚<br />
- è›‹ç™½è´¨ç»„ä¸è½¬å½•ç»„æ•°æ®æ•´åˆåˆ†æï¼ˆ10ï¼‰ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- æ–°å‹å¤šç»„å­¦æ•´åˆä¸ç½‘ç»œæ¨æ–­å·¥å…·ï¼ˆ1ï¼‰ã€‚<br />
- ç©ºé—´è½¬å½•ç»„æŠ€æœ¯æ€§èƒ½è¯„æ¯”ï¼ˆ6ï¼‰ã€‚<br />
- é€‚ç”¨äºå¤æ‚ç”Ÿç‰©æ•°æ®å¯è§†åŒ–çš„ggforceåŒ…ï¼ˆ17ï¼‰åŠåŸºå› ç‰¹å¾é€‰æ‹©çš„GeneSelectRå·¥å…·ï¼ˆ20ï¼‰ã€‚</p>
<h3>ğŸ§¬ æ•°æ®å‰æ²¿</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
Eukaryotic Translation Initiation Factor 3m åœ¨å¿ƒè‚Œç¼ºè¡€å†çŒæ³¨æŸä¼¤åï¼Œé€šè¿‡è°ƒæ§ç¡åŒ–æŸä¼¤ï¼Œæ­ç¤ºå…¶ä½œä¸ºå¿ƒåŠ›è¡°ç«­é¢„åæŒ‡æ ‡çš„ç‹¬ç‰¹ä½œç”¨ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- æ¢ç´¢ RNA ç»“åˆè›‹ç™½åœ¨å¿ƒè¡€ç®¡ç–¾ç—…ï¼ˆå¦‚å¿ƒåŠ›è¡°ç«­ã€è¡€ç®¡é’™åŒ–ï¼‰å’Œç‚ç—‡æ€§è‚ºç—…ï¼ˆARDSï¼‰ä¸­çš„è°ƒæ§æœºåˆ¶ã€‚<br />
- ç ”ç©¶ç»„è›‹ç™½ä¿®é¥°ï¼ˆå¦‚ä¹³é…°åŒ–ï¼‰ä¸è¡€ç®¡ç”Ÿæˆè½¬å½•è°ƒæ§çš„å…³ç³»ã€‚<br />
- è¯„ä¼° THOC5ã€SKIDA1ã€ORB2 ç­‰è›‹ç™½åœ¨ç»†èƒç¨³æ€ã€é€ è¡€å¹²ç»†èƒå‘è‚²å’Œè½¬å½•è°ƒæ§ä¸­çš„åŠŸèƒ½ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- å¤šç§é«˜é€šé‡æµ‹åºæŠ€æœ¯ï¼ˆClIP-Seq, Ribo-Seq, RNA-Seq, scRNA-Seq, ChIP-seq, RIP-seqï¼‰åœ¨ä¸åŒæ¨¡å¼ç”Ÿç‰©ï¼ˆäººã€é¼ ã€æœè‡ã€çŒ•çŒ´ï¼‰ä¸­å¹¿æ³›åº”ç”¨ï¼Œç»“åˆå¤šç»„å­¦åˆ†æï¼Œæ·±å…¥è§£æåˆ†å­æœºåˆ¶ã€‚</p>
<h3>ğŸ”¬ æœŸåˆŠæ–‡ç« </h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
*   <strong>äººé€ ç”œå‘³å‰‚æŸå®³ç™Œç—‡å…ç–«æ²»ç–—</strong>ï¼šç ”ç©¶å‘ç°éè¥å…»æ€§ç”œå‘³å‰‚é€šè¿‡å½±å“å¾®ç”Ÿç‰©ç¾¤å’Œä»£è°¢ç‰©ï¼Œå‰Šå¼±æŠ— PD-1 ç–—æ³•çš„ç–—æ•ˆï¼Œæç¤ºéœ€å…³æ³¨ç™Œç—‡æ‚£è€…çš„é•¿æœŸç”Ÿæ´»æ–¹å¼å¹²é¢„ã€‚<br />
*   <strong>æŠ—ä½“-è¯ç‰©å¶è”ç‰©ï¼ˆADCï¼‰çš„å˜é©æ€§åº”ç”¨</strong>ï¼šADC ç»“åˆäº†æŠ—ä½“é¶å‘æ€§å’Œç»†èƒæ¯’æ€§è¯ç‰©ï¼Œåœ¨æŠ—åŸè¯†åˆ«ã€å†…åŒ–ã€è¯ç‰©é‡Šæ”¾åŠè¯±å¯¼å…ç–«åŸæ€§ç»†èƒæ­»äº¡ç­‰æ–¹é¢å±•ç°å‡ºå·¨å¤§æ½œåŠ›ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
*   <strong>é¶å‘å‰åˆ—è…ºç™Œçš„ä»£è°¢è„†å¼±æ€§</strong>ï¼šåˆ©ç”¨éš”æ—¥ç¦é£Ÿï¼ˆADFï¼‰è¯±å¯¼é›„æ¿€ç´ å—ä½“ï¼ˆARï¼‰mRNAä¸Šçš„æ ¸ç³–ä½“ç¢°æ’ï¼ŒæŸå®³ARç¿»è¯‘ï¼Œä¸ºè€è¯æ€§å‰åˆ—è…ºç™Œæä¾›æ–°ç­–ç•¥ã€‚<br />
*   <strong>GLP-1æ¿€åŠ¨å‰‚ä¸è‚¥èƒ–/ç™Œç—‡å…³è”</strong>ï¼šæ¢ç´¢GLP-1æ¿€åŠ¨å‰‚åœ¨é€†è½¬è‚¥èƒ–ç—‡æ‚£è€…ç™Œç—‡é£é™©æ–¹é¢çš„æœºåˆ¶å’Œæ½œåŠ›ï¼Œéœ€æ›´å¤šä¸´åºŠå‰å’Œäººä½“ç ”ç©¶ã€‚<br />
*   <strong>è‚¿ç˜¤ç»†èƒä¼‘çœ æœºåˆ¶ç ”ç©¶</strong>ï¼šé‰´å®šè‚ºå†…çš®ç»†èƒä¸Šçš„PEAR1è›‹ç™½åœ¨ç»´æŒè‚¿ç˜¤ç»†èƒä¼‘çœ ä¸­çš„ä½œç”¨ï¼Œä¸ºç†è§£å’Œå¹²é¢„è¿œå¤„è½¬ç§»æä¾›æ–°è§†è§’ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
*   <strong>ARè›‹ç™½åˆæˆçš„ä»£è°¢è„†å¼±æ€§</strong>ï¼šæ­ç¤ºäº†é€šè¿‡ç‰¹å®šä»£è°¢å¹²é¢„ï¼ˆå¦‚ADFï¼‰å½±å“ARç¿»è¯‘çš„æ–°æœºåˆ¶ã€‚<br />
*   <strong>å†…çš®åˆ†æ³Œè›‹ç™½è°ƒæ§è‚¿ç˜¤ä¼‘çœ </strong>ï¼šå‘ç°äº†PEAR1ä½œä¸ºè°ƒèŠ‚è‚¿ç˜¤ç»†èƒä¼‘çœ çš„å…³é”®å†…çš®è›‹ç™½ã€‚</p>
<h3>ğŸ“Š å­¦ç‚¹ç”Ÿä¿¡</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
R Shiny å¼•å…¥è¡Œä¸ºé©±åŠ¨å¼€å‘ (BDD) çš„ Given æ­¥éª¤ï¼Œå®ç°æµ‹è¯•å‰ææ¡ä»¶è®¾ç½®ï¼›maestro 0.7.0 ç‰ˆæœ¬å®ç°æ¡ä»¶åŒ–ç®¡é“æ‰§è¡Œã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
* R Shiny åº”ç”¨æµ‹è¯•è‡ªåŠ¨åŒ–<br />
* ç”Ÿç‰©ä¿¡æ¯å­¦å·¥ä½œæµç®¡ç†</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
* R Shiny BDD ä¸­çš„ä¾èµ–æ³¨å…¥ã€æµ‹è¯•æ›¿èº«å’Œå¯ç»„åˆè®¾ç½®æ¨¡å¼<br />
* maestro æ¡ä»¶åŒ– DAG ç®¡é“åˆ†æ”¯æ‰§è¡Œ</p>
<h3>ğŸ§ª åšå®¢æ›´æ–°</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
é¦–æ¬¡åˆ©ç”¨å•ç»†èƒRNAæµ‹åºæ­ç¤ºäº†å·¨å™¬ç»†èƒå¹²æ‰°ç´ ä¿¡å·é€šè·¯åœ¨è‚¾ç™Œå…ç–«æ²»ç–—è€è¯ä¸­çš„å…³é”®ä½œç”¨ï¼Œä¸ºç”Ÿç‰©æ ‡å¿—ç‰©å‘ç°å’Œæ²»ç–—ç­–ç•¥ä¼˜åŒ–æä¾›æ–°æ€è·¯ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- è‚¾ç™Œå…ç–«æ²»ç–—è€è¯æœºåˆ¶ç ”ç©¶<br />
- ç–¾ç—…ç›¸å…³åŸºå› ï¼ˆå¦‚MAPT, BIN1ï¼‰çš„æ›¿ä»£æ€§RNAå‰ªæ¥è°ƒæ§æœºåˆ¶è§£æ<br />
- å…½åŒ»è¯Šæ–­ä¸åŠ¨ç‰©å¥åº·ç›‘æµ‹ä¸­çš„åŸºå› æµ‹åºåº”ç”¨</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- å•ç»†èƒRNAæµ‹åºï¼ˆscRNA-seqï¼‰<br />
- é•¿è¯»é•¿RNAæµ‹åºï¼ˆlong-read RNA-seqï¼‰</p>
            </div><h2>ğŸ“š åˆ†ç±»æµè§ˆ</h2>
<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ“° å…¬ä¼—å· (26æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>å¥åº·æˆå¹´äººå…ç–«è€åŒ–å…¨æ™¯å›¾ï¼›ç©ºé—´å¤šç»„å­¦æ™ºèƒ½æ•´åˆä¸è°ƒæ§ç½‘ç»œæ¨æ–­ã€å•ç»†èƒæ‰¹æ¬¡æ•´åˆã€å•ç»†èƒå¯å˜å‰ªåˆ‡ã€å‘è‚²æ½œèƒ½é¢„æµ‹ç­‰å·¥å…·ä¸Šæ–° |å•ç»†èƒè§†è§’</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šå•ç»†èƒå¤©åœ°<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå…ç–«ã€å•ç»†èƒã€ç©ºé—´ç»„å­¦<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzI1Njk4ODE0MQ==&amp;mid=2247533477&amp;idx=1&amp;sn=daf8c8ee0fd42dcd889437aac72a9a76" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> â­ <strong>9.4åˆ†éè‚¿ç˜¤ç”Ÿä¿¡ï¼Œè¡°è€+æœºå™¨å­¦ä¹ +åˆ†å‹+å…ç–«æµ¸æ¶¦+è¡¨è¾¾éªŒè¯ã€‚è¿™æˆ‘ä¹Ÿèƒ½åšå‘€ï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€å…ç–«ã€ç”Ÿä¿¡<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247503824&amp;idx=4&amp;sn=8f76b0533d1a608e8bb2ea6c4d894ade" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> â­ <strong>éè‚¿ç˜¤çº¯ç”Ÿä¿¡ï¼ŒåŸºäºæœºå™¨å­¦ä¹ ï¼Œæ— ç›‘ç£èšç±»ç­‰ç ”ç©¶ç»†èƒè¡°è€åœ¨ç–¾ç—…ä¸­çš„ç‰¹å¾ã€‚è¡°è€çƒ­ç‚¹ç»ä¹…ä¸è¡°ï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€ç”Ÿä¿¡ã€èšç±»<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247503824&amp;idx=2&amp;sn=c47f1a491567d4f934a11206dce7e27a" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> â­ <strong>æœ€æ–°8.1åˆ†éè‚¿ç˜¤ç”Ÿä¿¡ï¼Œé’ˆå¯¹PANoptosisçƒ­ç‚¹è¿›è¡Œæœºå™¨å­¦ä¹ +å•ç»†èƒç­›é€‰+ç®€å•éªŒè¯ï¼Œå…¨æ–‡åªæœ‰4ä¸ªFigureï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€å•ç»†èƒã€ç”Ÿä¿¡<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247503824&amp;idx=1&amp;sn=57ca959a005a04d9cd4410f16d895348" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> â­ <strong>å¤æ—¦å¤§å­¦å‘ Nat Cancer |ä¸´åºŠè¯•éªŒ+å•ç»†èƒæµ‹åºï¼Œçœ‹çœ‹ä»–ä»¬æ˜¯æ€ä¹ˆåšçš„</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡é’±åŒå­¦<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€æµ‹åºã€å•ç»†èƒ<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šä¸´åºŠå®éªŒé…åˆå•ç»†èƒæµ‹åº<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzkwMzY2NjkwNg==&amp;mid=2247495403&amp;idx=1&amp;sn=464b38cbd7349648d4d8113aec4d6f0c" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> â­ <strong>æ–‡çŒ®åˆ†äº«|Nature Communications: å››å¤§ç©ºé—´è½¬å½•ç»„å¹³å°æ€§èƒ½å¤§æ¯”æ‹¼ï¼šè°åœ¨è‚¿ç˜¤ç ”ç©¶ä¸­æ›´èƒœä¸€ç­¹ï¼Ÿ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç‹æ°¸æˆLab<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€ç©ºé—´è½¬å½•ç»„ã€è½¬å½•ç»„<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šNature Communicationsè¿‘å¹´æ¥ï¼Œç©ºé—´è½¬å½•ç»„å­¦æŠ€æœ¯åœ¨åˆ†è¾¨ç‡ä¸é€šé‡æ–¹é¢å–å¾—æ˜¾è‘—çªç ´ï¼Œä½†ç°æœ‰æŠ€æœ¯è¯„<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzkxMDY1MjU1OA==&amp;mid=2247488446&amp;idx=1&amp;sn=559764a9995cc412c84f5ebae068b2c7" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> <strong>æœ€æ–°5.7åˆ†ç”Ÿä¿¡ï¼Œå•ç»†èƒæ³›ç™Œ+ç©ºè½¬æ³›ç™Œ+ç™¾ç§æœºå™¨å­¦ä¹ ç ”ç©¶CAFçš„è¡°è€è¡¨å‹ï¼ŒæŠ•ç¨¿åˆ°æ¥æ”¶ä»…48å¤©ï¼Œå¯è°“æ˜¯æ°´åˆŠä¸­çš„å¤©èŠ±æ¿ï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå•ç»†èƒã€ç”Ÿä¿¡<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247503824&amp;idx=7&amp;sn=a41c1eee969ebc64c35bd1079c262907" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> <strong>5æœˆæœ€æ–°10+ç”Ÿä¿¡ï¼ŒåŸºäºç»†èƒæ­»äº¡å’Œè¡°è€çš„è‚¿ç˜¤åˆ†å‹åŠæ¨¡å‹æ„å»ºï¼Œåˆ†æä¸éš¾ï¼Œå®éªŒåªæœ‰åŠä¸ªfigureï¼Œå€¼å¾—å­¦ä¹ ï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€ç”Ÿä¿¡<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247503824&amp;idx=6&amp;sn=34a846bbfdc98165c172a8b3b8d8f4ef" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> <strong>15.7åˆ†çº¯ç”Ÿä¿¡ï¼ŒåŸºäºå•ç»†èƒæ„å»ºç»†èƒè¡°è€çš„ç»†èƒç±»å‹ç‰¹å¼‚æ€§å›¾è°±ã€‚è‡ªå®šä¹‰ç®—æ³•é‰´å®šå‡ºæ–°çš„è¡°è€åŸºå› é›†ï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå•ç»†èƒã€ç”Ÿä¿¡<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247503824&amp;idx=3&amp;sn=1eacdde390df0a070b63975b9c529cbe" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> <strong>è›‹ç™½è´¨ç»„è½¬å½•ç»„åˆ†æä¸¤ä¸‰äº‹ï¼šKEGGå·²ç»ä¸æ˜¯ä»¥å‰çš„KEGGäº†</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šDr.Xçš„åŸºå› ç©ºé—´<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè½¬å½•ç»„ã€è›‹ç™½è´¨ç»„<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šæ—§ä»£ç éœ€è¦å®šæœŸæ£€æŸ¥è¿è¡Œç¨³å®šæ€§ï¼Œç‰¹åˆ«æ˜¯ä»£ç ä¸­ä¾èµ–åˆ°ç¬¬ä¸‰æ–¹æ•°æ®åº“å’Œç½‘ç«™æ—¶ï¼Œéœ€è¦è­¦æƒ•å¤–éƒ¨å˜åŒ–ä¸ºå†…éƒ¨åˆ†æå¸¦æ¥ä¸å¯å¿½è§†çš„å½±å“<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzU3MTc2NDI4Mw==&amp;mid=2247486659&amp;idx=1&amp;sn=b3d0fd6f227a91f5306e359763dbb5ed" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 16 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-å…¬ä¼—å·">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (54æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>GSE217286 ç¼ºè¡€æ€§å¿ƒåŠ›è¡°ç«­é¢„åæŒ‡æ ‡çœŸæ ¸ç¿»è¯‘èµ·å§‹å› å­ 3m çš„ RNA ç»“åˆæ¨¡å¼æ­ç¤ºå…¶åœ¨å¿ƒè‚Œç¼ºè¡€å†çŒæ³¨åç¡åŒ–æŸä¼¤è°ƒæ§ä¸­çš„ç‹¬ç‰¹ä½œç”¨ [ClIP-Seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€cancerã€oncologyã€carcinomaã€leukemiaã€immuneã€immunityã€immunologyã€TMEã€cardiacã€gliomaã€kinaseã€resistanceã€TCGAã€DepMapã€depmapã€RNA-seqã€RNAseqã€DNA-seqã€ChIP-seqã€ATAC-seqã€Hi-Cã€single.cellã€scRNAã€scDNAã€scATACã€spatialã€spatiallyã€Visiumã€genomeã€genomicsã€proteomeã€proteomicsã€bioinformaticsã€R packageã€Bioconductorã€Seuratã€epigeneticã€epigenomeã€histoneã€enrichmentã€clustering<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Zilun Wei ; Yongchao Zhao ; Aijun Sun ; Junbo GeSeries Type : OtherOrganism : Homo sapiens ; Rattus norvegicusRNA undergoes various modifications in a manner similar to DNA, thereby opening up the research field of epitranscriptomics. Regulators of mRNA modifications play a role in many molecular processes, biological functions, and disease prognosis. Differential expression profile of RNA modification regulators from HFrEF patientsâ€™ hearts remains deficient at present, let alone their affections on the prognosis. A risk score model based on two modifications-related modulators (eIF3m and Nudt12) was built and screened out with a LASSO regression analysis. Translation dysregulation upon eIF3m knock down in cardiomyocytes was examined by combined high-throughput methods of transcriptome sequencing, ribosome profiling, proteome research, and Clip analyses. Metabolic assays and flux analysis were used to characterize the effects of eIF3m and its downstream mediator in metabolic reprogramming with high-level exogenous TNF-Î± to mimic a highly oxidative inflammatory injury. eIF3m deficiency leads to decoupling of the major steps in translation initiation and elongation. It stabilizes eIF3m-f-h subcomplex through proteasome dependent-polyubiquitination, and controls translational response of specific mRNAs. eIF3m directly binds to Mt2 5â€™ leader to upregulate its translation in NRCMs and H9c2 cells. eIF3m knockdown induced expression of genes involved in proinflammatory and oxidative stress, resulting in 3-NT modification to a key glycolysis enzyme Pfkfb3 when co-cultured with exogenous TNF-Î±. CM-specific eIF3m deletion deteriorates cardiac function and increases infarction size after I/R operation, whereas CM-specific eIF3m overexpression reverses the phenotype. Additionally, eIF3m overexpression inhibits whereas RNAi-mediated Mt2 knockdown activates NF-ÎºB signaling and aggravates nitrative damage. Metabolic analyses highlighted the role for eIF3m in promoting glycolysis and biosynthesis required for functional recovery of the myocardium. Our study demonstrates that the prognosis indicator eIF3m alleviates oxidative inflammatory injury and promotes glycolytic reprograming mainly by binding to Mt2 mRNA. Therapeutic strategies enhancing eIF3m level may possess therapeutic potential against I/R injury.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE217286" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> â­ <strong>GSE217295 ç¼ºè¡€æ€§å¿ƒåŠ›è¡°ç«­é¢„åæŒ‡æ ‡çœŸæ ¸ç¿»è¯‘èµ·å§‹å› å­ 3m çš„ RNA ç»“åˆæ¨¡å¼æ­ç¤ºå…¶åœ¨å¿ƒè‚Œç¼ºè¡€å†çŒæ³¨åç¡åŒ–æŸä¼¤è°ƒèŠ‚ä¸­çš„ç‹¬ç‰¹ä½œç”¨ [Ribo-Seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€cancerã€oncologyã€carcinomaã€leukemiaã€immuneã€immunityã€immunologyã€TMEã€cardiacã€gliomaã€kinaseã€resistanceã€TCGAã€DepMapã€depmapã€RNA-seqã€RNAseqã€DNA-seqã€ChIP-seqã€ATAC-seqã€single.cellã€scRNAã€scDNAã€scATACã€spatialã€spatiallyã€Visiumã€genomeã€genomicsã€proteomeã€proteomicsã€bioinformaticsã€R packageã€Bioconductorã€Seuratã€epigeneticã€epigenomeã€histoneã€enrichmentã€clustering<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Zilun Wei ; Yongchao Zhao ; Aijun Sun ; Junbo GeSeries Type : Expression profiling by high throughput sequencing ; OtherOrganism : Rattus norvegicusRNA undergoes various modifications in a manner similar to DNA, thereby opening up the research field of epitranscriptomics. Regulators of mRNA modifications play a role in many molecular processes, biological functions, and disease prognosis. Differential expression profile of RNA modification regulators from HFrEF patientsâ€™ hearts remains deficient at present, let alone their affections on the prognosis. A risk score model based on two modifications-related modulators (eIF3m and Nudt12) was built and screened out with a LASSO regression analysis. Translation dysregulation upon eIF3m knock down in cardiomyocytes was examined by combined high-throughput methods of transcriptome sequencing, ribosome profiling, proteome research, and Clip analyses. Metabolic assays and flux analysis were used to characterize the effects of eIF3m and its downstream mediator in metabolic reprogramming with high-level exogenous TNF-Î± to mimic a highly oxidative inflammatory injury. eIF3m deficiency leads to decoupling of the major steps in translation initiation and elongation. It stabilizes eIF3m-f-h subcomplex through proteasome dependent-polyubiquitination, and controls translational response of specific mRNAs. eIF3m directly binds to Mt2 5â€™ leader to upregulate its translation in NRCMs and H9c2 cells. eIF3m knockdown induced expression of genes involved in proinflammatory and oxidative stress, resulting in 3-NT modification to a key glycolysis enzyme Pfkfb3 when co-cultured with exogenous TNF-Î±. CM-specific eIF3m deletion deteriorates cardiac function and increases infarction size after I/R operation, whereas CM-specific eIF3m overexpression reverses the phenotype. Additionally, eIF3m overexpression inhibits whereas RNAi-mediated Mt2 knockdown activates NF-ÎºB signaling and aggravates nitrative damage. Metabolic analyses highlighted the role for eIF3m in promoting glycolysis and biosynthesis required for functional recovery of the myocardium. Our study demonstrates that the prognosis indicator eIF3m alleviates oxidative inflammatory injury and promotes glycolytic reprograming mainly by binding to Mt2 mRNA. Therapeutic strategies enhancing eIF3m level may possess therapeutic potential against I/R injury.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE217295" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> â­ <strong>GSE217293 ç¼ºè¡€æ€§å¿ƒåŠ›è¡°ç«­é¢„åæŒ‡æ ‡çœŸæ ¸ç¿»è¯‘èµ·å§‹å› å­ 3m çš„ RNA ç»“åˆæ¨¡å¼æ­ç¤ºå…¶åœ¨å¿ƒè‚Œç¼ºè¡€å†çŒæ³¨åç¡åŒ–æŸä¼¤è°ƒæ§ä¸­çš„ç‹¬ç‰¹ä½œç”¨ [RNA-Seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€cancerã€oncologyã€carcinomaã€leukemiaã€immuneã€immunityã€immunologyã€TMEã€cardiacã€gliomaã€kinaseã€resistanceã€TCGAã€DepMapã€depmapã€RNA-seqã€RNAseqã€DNA-seqã€ChIP-seqã€ATAC-seqã€single.cellã€scRNAã€scDNAã€scATACã€spatialã€spatiallyã€Visiumã€genomeã€genomicsã€proteomeã€proteomicsã€bioinformaticsã€R packageã€Bioconductorã€Seuratã€epigeneticã€epigenomeã€histoneã€enrichmentã€clustering<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Zilun Wei ; Yongchao Zhao ; Aijun Sun ; Junbo GeSeries Type : Expression profiling by high throughput sequencingOrganism : Rattus norvegicusRNA undergoes various modifications in a manner similar to DNA, thereby opening up the research field of epitranscriptomics. Regulators of mRNA modifications play a role in many molecular processes, biological functions, and disease prognosis. Differential expression profile of RNA modification regulators from HFrEF patientsâ€™ hearts remains deficient at present, let alone their affections on the prognosis. A risk score model based on two modifications-related modulators (eIF3m and Nudt12) was built and screened out with a LASSO regression analysis. Translation dysregulation upon eIF3m knock down in cardiomyocytes was examined by combined high-throughput methods of transcriptome sequencing, ribosome profiling, proteome research, and Clip analyses. Metabolic assays and flux analysis were used to characterize the effects of eIF3m and its downstream mediator in metabolic reprogramming with high-level exogenous TNF-Î± to mimic a highly oxidative inflammatory injury. eIF3m deficiency leads to decoupling of the major steps in translation initiation and elongation. It stabilizes eIF3m-f-h subcomplex through proteasome dependent-polyubiquitination, and controls translational response of specific mRNAs. eIF3m directly binds to Mt2 5â€™ leader to upregulate its translation in NRCMs and H9c2 cells. eIF3m knockdown induced expression of genes involved in proinflammatory and oxidative stress, resulting in 3-NT modification to a key glycolysis enzyme Pfkfb3 when co-cultured with exogenous TNF-Î±. CM-specific eIF3m deletion deteriorates cardiac function and increases infarction size after I/R operation, whereas CM-specific eIF3m overexpression reverses the phenotype. Additionally, eIF3m overexpression inhibits whereas RNAi-mediated Mt2 knockdown activates NF-ÎºB signaling and aggravates nitrative damage. Metabolic analyses highlighted the role for eIF3m in promoting glycolysis and biosynthesis required for functional recovery of the myocardium. Our study demonstrates that the prognosis indicator eIF3m alleviates oxidative inflammatory injury and promotes glycolytic reprograming mainly by binding to Mt2 mRNA. Therapeutic strategies enhancing eIF3m level may possess therapeutic potential against I/R injury.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE217293" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> â­ <strong>GSE217285 ç¼ºè¡€æ€§å¿ƒåŠ›è¡°ç«­é¢„åæŒ‡æ ‡çœŸæ ¸ç¿»è¯‘èµ·å§‹å› å­ 3m çš„ RNA ç»“åˆæ¨¡å¼æ­ç¤ºå…¶åœ¨å¿ƒè‚Œç¼ºè¡€å†çŒæ³¨åç¡åŒ–æŸä¼¤è°ƒæ§ä¸­çš„ç‹¬ç‰¹ä½œç”¨ [Mt2RNAseq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€cancerã€oncologyã€carcinomaã€leukemiaã€immuneã€immunityã€immunologyã€TMEã€cardiacã€gliomaã€kinaseã€resistanceã€TCGAã€DepMapã€depmapã€RNA-seqã€RNAseqã€DNA-seqã€ChIP-seqã€ATAC-seqã€single.cellã€scRNAã€scDNAã€scATACã€spatialã€spatiallyã€Visiumã€genomeã€genomicsã€proteomeã€proteomicsã€bioinformaticsã€R packageã€Bioconductorã€Seuratã€epigeneticã€epigenomeã€histoneã€enrichmentã€clustering<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Zilun Wei ; Yongchao Zhao ; Aijun Sun ; Junbo GeSeries Type : Expression profiling by high throughput sequencingOrganism : Rattus norvegicusRNA undergoes various modifications in a manner similar to DNA, thereby opening up the research field of epitranscriptomics. Regulators of mRNA modifications play a role in many molecular processes, biological functions, and disease prognosis. Differential expression profile of RNA modification regulators from HFrEF patientsâ€™ hearts remains deficient at present, let alone their affections on the prognosis. A risk score model based on two modifications-related modulators (eIF3m and Nudt12) was built and screened out with a LASSO regression analysis. Translation dysregulation upon eIF3m knock down in cardiomyocytes was examined by combined high-throughput methods of transcriptome sequencing, ribosome profiling, proteome research, and Clip analyses. Metabolic assays and flux analysis were used to characterize the effects of eIF3m and its downstream mediator in metabolic reprogramming with high-level exogenous TNF-Î± to mimic a highly oxidative inflammatory injury. eIF3m deficiency leads to decoupling of the major steps in translation initiation and elongation. It stabilizes eIF3m-f-h subcomplex through proteasome dependent-polyubiquitination, and controls translational response of specific mRNAs. eIF3m directly binds to Mt2 5â€™ leader to upregulate its translation in NRCMs and H9c2 cells. eIF3m knockdown induced expression of genes involved in proinflammatory and oxidative stress, resulting in 3-NT modification to a key glycolysis enzyme Pfkfb3 when co-cultured with exogenous TNF-Î±. CM-specific eIF3m deletion deteriorates cardiac function and increases infarction size after I/R operation, whereas CM-specific eIF3m overexpression reverses the phenotype. Additionally, eIF3m overexpression inhibits whereas RNAi-mediated Mt2 knockdown activates NF-ÎºB signaling and aggravates nitrative damage. Metabolic analyses highlighted the role for eIF3m in promoting glycolysis and biosynthesis required for functional recovery of the myocardium. Our study demonstrates that the prognosis indicator eIF3m alleviates oxidative inflammatory injury and promotes glycolytic reprograming mainly by binding to Mt2 mRNA. Therapeutic strategies enhancing eIF3m level may possess therapeutic potential against I/R injury.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE217285" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> â­ <strong>GSE217296 RNA ç»“åˆæ¨¡å¼æ­ç¤ºäº†ç¼ºè¡€æ€§å¿ƒåŠ›è¡°ç«­é¢„åæŒ‡æ ‡çœŸæ ¸ç¿»è¯‘èµ·å§‹å› å­ 3m åœ¨å¿ƒè‚Œç¼ºè¡€å†çŒæ³¨åç¡åŒ–æŸä¼¤è°ƒæ§ä¸­çš„ç‹¬ç‰¹ä½œç”¨ï¼Œæç¤ºå…¶åœ¨å¿ƒè‚Œç¼ºè¡€å†çŒæ³¨æŸä¼¤è°ƒæ§ä¸­å‘æŒ¥é‡è¦ä½œç”¨ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€cancerã€oncologyã€carcinomaã€leukemiaã€immuneã€immunityã€immunologyã€TMEã€cardiacã€gliomaã€kinaseã€resistanceã€TCGAã€DepMapã€depmapã€RNAseqã€single.cellã€scRNAã€scDNAã€scATACã€spatialã€spatiallyã€Visiumã€genomeã€genomicsã€proteomeã€proteomicsã€bioinformaticsã€R packageã€Bioconductorã€Seuratã€epigeneticã€epigenomeã€histoneã€enrichmentã€clustering<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSeries Type : Expression profiling by high throughput sequencing ; OtherOrganism : Homo sapiens ; Rattus norvegicusThis SuperSeries is composed of the SubSeries listed below.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE217296" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> â­ <strong>GSE281368 THOC5 ä¾èµ–æ€§è½¬å½•åæ§åˆ¶ç»´æŒè¡€ç®¡å¹³æ»‘è‚Œç»†èƒç¨³æ€ï¼Œå¯¹æŠ—æ…¢æ€§è‚¾è„ç—…ç›¸å…³è¡€ç®¡é’™åŒ– [RIP-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€cancerã€oncologyã€carcinomaã€immuneã€TMEã€cardiacã€gliomaã€kinaseã€TCGAã€DepMapã€depmapã€RNA-seqã€RNAseqã€DNA-seqã€ChIP-seqã€ATAC-seqã€scRNAã€scDNAã€scATACã€spatialã€spatiallyã€genomeã€genomicsã€transcriptomeã€transcriptomicsã€proteomeã€proteomicsã€Seuratã€Scanpyã€methylationã€histoneã€enrichment<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSeries Type : OtherOrganism : Mus musculusBackground: Despite transcriptional control mechanisms of VSMC osteogenic transition having been extensively studied, posttranscriptional regulation is still awaiting elucidation. In the present study, we explore the mechanism of THOC5-dependent VSMCs osteochondrogenic switching. Methods: Von Kossa staining and immunohistochemistry staining were used to detect calcification and expression of THOC5 respectively. Thoc5 shRNA and Thoc5 overexpression lentivirus were used to modulate the expression of Thoc5. RNA-Seq combined with RIP-Seq was used to explore the target mRNAs that directly bind to THOC5, and FISH was used to confirm its subcellular localization. Results: Immunohistochemical staining showed significantly increased THOC5 expression in the calcified artery of CKD patients. Besides, calcification-induced increase of THOC5 expression was found in both in vivo and in vitro calcification models. The overexpression of Thoc5 relieves the calcification and osteogenic differentiation of VSMCs significantly in vitro, which is mainly manifested by the reduction of calcium ion deposition and the decreased expression of osteogenic markers. Furthermore, RNA-Seq revealed that THOC5 overexpression in osteogenic-induced VSMCs closely resembled the gene expression changes induced on TGF-Î² treatments in cultured VSMCs. In addition, overexpression of THOC5 alleviates the exacerbation of calcification in vivo. Our previous studies found that THOC5 displayed limited binding to VSMCs genomic DNA, so RIP-Seq was selected to detect target genes of THOC5. It was found that THOC5 directly interacts with Guanylate exchange factors (GEFs) mRNAs, and is required for their export. Thereby THOC5 maintaining RhoA GTPase activation contributes to increasing the expression of VSMCs contraction marker, which maintains the contraction phenotype of VSMCs. ROCK (Rho-kinase) inhibitor Y-27632 reversed the protective role of THOC5 on osteoblastic transdifferentiation and calcification, as well as the maintenance of the spindle morphology of VSMCs. Conclusions: Our data introduce the binding of THOC5 to GEFs as a novel mechanism contributing to maintaining VSMCs homeostasis and imply THOC5 as a potential intervention node for vascular calcification diseases.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE281368" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> â­ <strong>GSE309106 å•ç»†èƒ RNA æµ‹åºæ­ç¤ºäº†èŠ³çƒƒå—ä½“æ¿€æ´»é€šè¿‡æ¶‰åŠè‚ºéƒ¨å…ç–«ç»†èƒå’Œä¸Šçš®ç»†èƒçš„å¤šæ¡é€šè·¯å‡è½»æ€¥æ€§å‘¼å¸çª˜è¿«ç»¼åˆå¾</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€cancerã€immuneã€immunityã€TMEã€cardiacã€gliomaã€resistanceã€TCGAã€sequencingã€RNAseqã€single.cellã€single-cellã€scRNAã€scDNAã€scATACã€spatialã€spatiallyã€Visiumã€genomeã€genomicsã€transcriptomeã€proteomeã€Seuratã€Scanpyã€epigeneticã€epigenomeã€methylationã€histoneã€pathwayã€clustering<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributor : Mitzi NagarkattiSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusAcute Respiratory Distress Syndrome (ARDS) is a severe inflammatory lung disorder triggered by pneumonia, sepsis, trauma, and COVID-19, leading to high mortality. In this study, we investigated the effect of Aryl Hydrocarbon Receptor (AhR) activation by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a potent ligand, on LPS-induced ARDS in mice using single-cell RNA sequencing (scRNA-seq). scRNA-seq revealed sixteen transcriptionally distinct cell clusters in the lungs. AhR activation reversed the decreased pulmonary functions caused by LPS, and significantly reduced pulmonary infiltration of monocytes, neutrophils, and macrophages. Interestingly, AhR activation during ARDS led to increased proportions of alveolar macrophages, and angiogenic and quiescent endothelial cells (AECs and QECs, respectively). Among the downregulated pathways, prostaglandin signaling was the most broadly suppressed across many cell types in the LPS+TCDD group. AhR activation suppressed the neutrophil chemotaxis pathway involving Cxcl2, Cxcl3, and Cxcl10. The damage to endothelial and epithelial cells induced during ARDS was also blocked by AhR activation. This was associated with decreased expression of S100a8 and S100a9. Notably, multiple pathways related to cellular junction organization were enriched following AhR activation. Additionally, Scgb1a1, also called Club cell protein 16 (CC16), primarily secreted by Club cells in the respiratory epithelium, was highly upregulated following AhR activation accounting for lung homeostasis. Together, these findings demonstrate that AhR activation mitigates key inflammatory and barrier-disruptive processes involving multiple cell types in LPS-induced ARDS. These data identify AhR as a central regulator of pulmonary inflammation and epithelialâ€“endothelial integrity and support the future evaluation of AhR-targeted therapeutics as potential treatment for ARDS.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309106" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> â­ <strong>GSE281115 THOC5 ä¾èµ–æ€§è½¬å½•åæ§åˆ¶ç»´æŒè¡€ç®¡å¹³æ»‘è‚Œç»†èƒç¨³æ€ï¼ŒæŠµæŠ—æ…¢æ€§è‚¾è„ç—…ç›¸å…³è¡€ç®¡é’™åŒ– [RNA-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€cancerã€oncologyã€carcinomaã€immuneã€TMEã€cardiacã€gliomaã€kinaseã€TCGAã€RNA-seqã€RNAseqã€DNA-seqã€ATAC-seqã€scRNAã€scDNAã€scATACã€spatialã€spatiallyã€genomeã€genomicsã€transcriptomeã€transcriptomicsã€proteomeã€proteomicsã€Seuratã€Scanpyã€methylationã€histoneã€enrichment<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusBackground: Despite transcriptional control mechanisms of VSMC osteogenic transition having been extensively studied, posttranscriptional regulation is still awaiting elucidation. In the present study, we explore the mechanism of THOC5-dependent VSMCs osteochondrogenic switching. Methods: Von Kossa staining and immunohistochemistry staining were used to detect calcification and expression of THOC5 respectively. Thoc5 shRNA and Thoc5 overexpression lentivirus were used to modulate the expression of Thoc5. RNA-Seq combined with RIP-Seq was used to explore the target mRNAs that directly bind to THOC5, and FISH was used to confirm its subcellular localization. Results: Immunohistochemical staining showed significantly increased THOC5 expression in the calcified artery of CKD patients. Besides, calcification-induced increase of THOC5 expression was found in both in vivo and in vitro calcification models. The overexpression of Thoc5 relieves the calcification and osteogenic differentiation of VSMCs significantly in vitro, which is mainly manifested by the reduction of calcium ion deposition and the decreased expression of osteogenic markers. Furthermore, RNA-Seq revealed that THOC5 overexpression in osteogenic-induced VSMCs closely resembled the gene expression changes induced on TGF-Î² treatments in cultured VSMCs. In addition, overexpression of THOC5 alleviates the exacerbation of calcification in vivo. Our previous studies found that THOC5 displayed limited binding to VSMCs genomic DNA, so RIP-Seq was selected to detect target genes of THOC5. It was found that THOC5 directly interacts with Guanylate exchange factors (GEFs) mRNAs, and is required for their export. Thereby THOC5 maintaining RhoA GTPase activation contributes to increasing the expression of VSMCs contraction marker, which maintains the contraction phenotype of VSMCs. ROCK (Rho-kinase) inhibitor Y-27632 reversed the protective role of THOC5 on osteoblastic transdifferentiation and calcification, as well as the maintenance of the spindle morphology of VSMCs. Conclusions: Our data introduce the binding of THOC5 to GEFs as a novel mechanism contributing to maintaining VSMCs homeostasis and imply THOC5 as a potential intervention node for vascular calcification diseases.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE281115" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> â­ <strong>GSE300680 äººç±»å•æ ¸ç»†èƒè¡ç”Ÿå·¨å™¬ç»†èƒçš„ç”Ÿæˆå’Œå¤šç»„å­¦åˆ†æçš„ç®€åŒ–å’Œç»¼åˆæ–¹æ¡ˆ [bulk RNA-Seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€cancerã€oncologyã€immuneã€TMEã€gliomaã€TCGAã€DepMapã€depmapã€RNA-seqã€RNAseqã€DNA-seqã€ChIP-seqã€ATAC-seqã€Hi-Cã€scRNAã€scDNAã€scATACã€spatialã€spatiallyã€Visiumã€genomeã€genomicsã€proteomeã€proteomicsã€epigeneticã€epigenomeã€histone<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Olivia G Palmer ; Laurent Perreard ; Fred W Kolling IV ; Patricia A Pioli ; Brittany A GoodsSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensMacrophages are versatile immune cells with phenotypes ranging from inflammatory (M1-like) to anti-inflammatory (M2-like), shaped by diverse differentiation and polarization conditions. We present a standardized protocol to generate and characterize human macrophages from frozen PBMC-derived monocytes using cytokine profiling, transcriptomics, and snRNA-seq, including depolarization studies. This streamlined approach facilitates reproducible macrophage studies from biobanked samples, advancing both research and therapeutic applications.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE300680" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> â­ <strong>GSE293108 SKIDA1 åœ¨æ–°ç”Ÿå„¿æœŸçŸ­æš‚ç»´æŒ MLL::ENL è¡¨è¾¾çš„é€ è¡€ç¥–ç»†èƒï¼Œå¹¶ä¿ƒè¿› B ç»†èƒè°±ç³»å¯åŠ¨ [scRNA-Seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€lymphomaã€immuneã€TMEã€gliomaã€kinaseã€resistanceã€TCGAã€DepMapã€depmapã€RNA-seqã€RNAseqã€DNA-seqã€ATAC-seqã€Hi-Cã€scRNAã€scDNAã€scATACã€10xã€spatialã€genomeã€genomicsã€proteomeã€proteomicsã€Seuratã€epigeneticã€epigenomeã€histone<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Jonny Mendoza-Castrejon ; Jeffrey A MageeSeries Type : Expression profiling by high throughput sequencing ; OtherOrganism : Mus musculusTo assess changes in transcriptional responses to Skida1 deletion in the context of MLL::ENL, we performed CITE-seq on Tet-Off-ME mice.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293108" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 44 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-æ•°æ®å‰æ²¿">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ”¬ æœŸåˆŠæ–‡ç«  (7æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨7æ¡ï¼‰</h4>
<p><strong>1.</strong> <strong>äººé€ ç”œå‘³å‰‚åœ¨ç™Œç—‡å…ç–«æ²»ç–—ä¸­çš„è‹¦æ¶©å›å‘³</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šç™Œç—‡ã€å…ç–«<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: æ‘˜è¦ï¼šMorderã€Nguyenã€Wilfahrt åŠå…¶åŒäº‹æŠ¥å‘Šè¯´ï¼Œéè¥å…»æ€§ç”œå‘³å‰‚é€šè¿‡æ¶‰åŠå¾®ç”Ÿç‰©ç¾¤å’Œä»£è°¢ç‰©è°ƒèŠ‚çš„æœºåˆ¶æŸå®³æŠ— PD-1 æ²»ç–—çš„ç–—æ•ˆã€‚ä»–ä»¬çš„ç ”ç©¶ç»“æœå¼ºè°ƒäº†å¤šç§ç™Œç—‡ç±»å‹é•¿æœŸç”Ÿæ´»æ–¹å¼å¹²é¢„çš„ä¸´åºŠç›¸å…³æ€§ï¼Œä¾‹å¦‚é™åˆ¶éè¥å…»æ€§ç”œå‘³å‰‚çš„æ¯æ—¥æ‘„å…¥é‡ã€‚å‚è§ Morder ç­‰äººçš„ç›¸å…³æ–‡ç« ï¼Œç¬¬ 2278 é¡µ<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1985400838140108800/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> <strong>äººç±»ç™Œç—‡å±æœºï¼šæŸ³å¶åˆ€è‚¿ç˜¤å­¦å§”å‘˜ä¼š</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€ç™Œç—‡<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: åœ¨è‚¿ç˜¤å­¦é¢†åŸŸå‰æ‰€æœªæœ‰çš„ç§‘å­¦è¿›æ­¥ä¸­ï¼Œè¶Šæ¥è¶Šå¤šçš„è¯æ®è¡¨æ˜ï¼Œäººç±»ç™Œç—‡æŠ¤ç†ç»å†ä¸­å­˜åœ¨ç€å¹³è¡Œè€Œæ·±åˆ»çš„å±æœºã€‚å°½ç®¡æ€»ä½“ç”Ÿå­˜ç»“æœæœ‰æ‰€æ”¹å–„ï¼Œä½†æ—¨åœ¨æä¾›æŠ¤ç†çš„ç³»ç»Ÿåœ¨è§£å†³ç™Œç—‡çš„æƒ…æ„Ÿã€å…³ç³»å’Œç”Ÿå­˜æ–¹é¢è¶Šæ¥è¶Šä¸è¶³ã€‚å°½ç®¡åœ¨æ¯ç§ç¯å¢ƒä¸­éƒ½å¯ä»¥æ‰¾åˆ°å¯Œæœ‰åŒæƒ…å¿ƒå’Œç»†å¿ƒæŠ¤ç†çš„ä¾‹å­ï¼Œä½†å…¨çƒèŒƒå›´å†…çš„æ‚£è€…å’Œå®¶å±ä»ç„¶æŠ¥å‘Šè¯´ï¼Œç”±äºä¼˜å…ˆè€ƒè™‘æŠ€æœ¯ç²¾ç¡®æ€§è€Œä¸æ˜¯äººç±»å­˜åœ¨çš„æŠ¤ç†ç»“æ„ï¼Œä»–ä»¬æ²¡æœ‰è¢«å€¾å¬ã€æ²¡æœ‰æ”¯æŒï¼Œæœ‰æ—¶ç”šè‡³å—åˆ°ç§¯æä¼¤å®³ã€‚æœ¬ã€Š æŸ³å¶åˆ€è‚¿ç˜¤å­¦å§”å‘˜ä¼šã€‹æå‡ºï¼Œäººç±»ç™Œç—‡å±æœºä¸æ˜¯ç”±ç—…ç†å­¦ã€æ­»äº¡ç‡æˆ–åŸå› å®šä¹‰çš„ï¼Œè€Œæ˜¯ç”±ç™Œç—‡ç»å†ä¸­æ„ä¹‰ã€è”ç³»å’ŒåŒæƒ…å¿ƒçš„ä¾µèš€æ¥å®šä¹‰çš„ã€‚è¿™åœºå±æœºæ˜¯ç”±å­˜åœ¨å’Œä¸å­˜åœ¨çš„ä¸œè¥¿å†³å®šçš„ï¼šæ”¯ç¦»ç ´ç¢ã€æ˜‚è´µå’Œç¼ºä¹ä¸ªäººåŒ–çš„ç³»ç»Ÿçš„å­˜åœ¨ï¼Œä»¥åŠäººé™…è”ç³»ã€å¿ƒç†å®‰å…¨å’Œå…³ç³»å…³æ€€çš„ç¼ºå¤±ã€‚è¿™æ˜¯ä¸€åœºæ¶µç›–åˆ†å¨©ã€å¿ƒç†å¥åº·ã€å§‘æ¯æ²»ç–—ã€ç ”ç©¶å’Œæ•™è‚²çš„å±æœºâ€”â€”è¿™åœºå±æœºä¸æ˜¯è‚¿ç˜¤å­¦è¿›æ­¥çš„è¾¹ç¼˜ï¼Œè€Œæ˜¯å…¶å¤±è´¥çš„æ ¸å¿ƒã€‚é‚£äº›å·²ç»å› ä¸å¹³ç­‰ã€æ­§è§†å’Œç»æµä¸ç¨³å®šè€Œå˜å¾—è„†å¼±çš„äººæ„Ÿå—åˆ°äº†è¿™åœºå±æœºçš„å½±å“æœ€ä¸ºå¼º<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1985482800108314624/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> <strong>åˆ©ç”¨å‰åˆ—è…ºç™Œä¸­çš„ AR ååŒä»£è°¢è„†å¼±æ€§</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šä»£è°¢<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: å¯¹é›„æ¿€ç´ å‰¥å¤ºç–—æ³•çš„è€è¯æ€§ä»ç„¶æ˜¯å‰åˆ—è…ºç™Œçš„ä¸»è¦ä¸´åºŠæŒ‘æˆ˜ï¼Œéœ€è¦æ›¿ä»£æ²»ç–—ç­–ç•¥ã€‚é›„æ¿€ç´ å—ä½“ ï¼ˆARï¼‰ é€šè¿‡å¢å¼º AR ä¿¡å·ä¼ å¯¼ã€DNA ä¿®å¤å’Œè‡ªå™¬ç­‰æœºåˆ¶åœ¨é©±åŠ¨è€è¯æ€§æ–¹é¢å‘æŒ¥æ ¸å¿ƒä½œç”¨ã€‚åœ¨æœ¬æœŸã€Šç™Œç—‡ç ”ç©¶ã€‹ä¸­ï¼ŒCordova åŠå…¶åŒäº‹å‘ç°äº† AR è›‹ç™½åˆæˆä¸­çš„ä»£è°¢è„†å¼±æ€§ï¼Œè¡¨æ˜éš”æ—¥ç¦é£Ÿ ï¼ˆADFï¼‰ é€šè¿‡è¯±å¯¼ AR mRNA ä¸Šçš„æ ¸ç³–ä½“ç¢°æ’æ¥æŸå®³ AR ç¿»è¯‘ã€‚è¿™ç§åº”æ¿€ååº”æ¿€æ´»æ¿€é…¶ï¼Œä¾‹å¦‚ p38 MAPKï¼Œå¹¶é€‰æ‹©æ€§åœ°é™ä½ AR è›‹ç™½æ°´å¹³ï¼Œä¸è½¬å½•æˆ–è›‹ç™½è´¨ç¨³å®šæ€§æ— å…³ã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼ŒADF å¢å¼ºäº†æ©æ‚é²èƒºåœ¨å¤šç§å‰åˆ—è…ºç™Œæ¨¡å‹ä¸­çš„ç–—æ•ˆã€‚ä¸ä¼ ç»Ÿçš„ AR é¶å‘æ–¹æ³•ä¸åŒï¼ŒADF æ­ç¤ºäº†è¥å…»èƒè¿«ä¸‹ AR è¡¨è¾¾çš„è½¬å½•åä¾èµ–æ€§ï¼ŒåŒæ—¶ä¿ç•™äº†å¤§å¤šæ•°å…¶ä»–è›‹ç™½è´¨ã€‚è¿™äº›å‘ç°å‡¸æ˜¾äº†å‰åˆ—è…ºç™Œä¸­ä¸€ç§æ–°çš„è½¬åŒ–è„†å¼±æ€§ï¼Œå¹¶æ”¯æŒå°†é¥®é£Ÿå¹²é¢„ä¸ AR é¶å‘ç–—æ³•ç›¸ç»“åˆï¼Œä»¥å…‹æœè€è¯æ€§å¹¶æ”¹å–„æ‚£è€…çš„é¢„åã€‚å‚è§ Cordova ç­‰äººçš„ç›¸å…³æ–‡ç« ï¼Œç¬¬ 4182 é¡µ<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1985400849754136576/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> <strong>GLP-1 æ¿€åŠ¨å‰‚ä¼šå‰Šå¼±è‚¥èƒ–ä¸ç™Œç—‡ä¹‹é—´çš„è”ç³»å—ï¼Ÿ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šç™Œç—‡<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: æ‘˜è¦ï¼šèƒ°é«˜è¡€ç³–ç´ æ ·è‚½1å—ä½“æ¿€åŠ¨å‰‚åœ¨é€†è½¬è‚¥èƒ–ç—‡æ‚£è€…çš„ä¸€äº›ç™Œç—‡é£é™©æ–¹é¢æœ‰å¾ˆå¤§çš„å¸Œæœ›ï¼Œåˆ°ç›®å‰ä¸ºæ­¢ï¼Œæ–°å…´çš„ä¸´åºŠè¯•éªŒæ”¯æŒè¿™ä¸€ç‚¹ã€‚ç„¶è€Œï¼Œä¸€äº›ä¸´åºŠå‰å·¥ä½œå’Œäººä½“ç ”ç©¶çš„è­¦å‘Šå¼ºè°ƒï¼Œéœ€è¦æ›´å¤šçš„å·¥ä½œæ¥äº†è§£æŠ—è‚¥èƒ–è¯ç‰©åœ¨ç™Œç—‡ä¸­çš„æœºåˆ¶å’Œå…¨éƒ¨æ½œåŠ›ã€‚<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1985400844523839488/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> <strong>ä»åˆ›æ–°åˆ°å½±å“åŠ›ï¼šå…±åŒæ¨è¿›ç™Œç—‡ç ”ç©¶</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šç™Œç—‡<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: æ‘˜è¦ï¼šç™Œç—‡ç ”ç©¶å·²è¿›å…¥ä¸€ä¸ªå˜é©æ—¶ä»£ï¼Œå…¶ç‰¹ç‚¹æ˜¯å…ç–«ç–—æ³•ã€æ—©æœŸæ£€æµ‹ã€ç²¾å‡†è‚¿ç˜¤å­¦å’Œäººå·¥æ™ºèƒ½çš„å¿«é€Ÿè¿›æ­¥æ­£åœ¨é‡å¡‘é¢„é˜²ã€æ²»ç–—å’Œç”Ÿå­˜ç‡ã€‚ä¸ºäº†ä¿æŒåŠ¿å¤´ï¼Œå…¨çƒç™Œç—‡ç•Œå¿…é¡»å›´ç»•æŠ•èµ„ã€åˆä½œå’Œå…¬å¹³å›¢ç»“èµ·æ¥ï¼Œä»¥ç¡®ä¿æ¯ä½æ‚£è€…éƒ½èƒ½ä»è¿™äº›çªç ´ä¸­å—ç›Šã€‚<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1985400861754040320/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> <strong>è‚ºå†…çš® PEAR1 è¯±å¯¼è‚¿ç˜¤ç»†èƒä¼‘çœ </strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: åœ¨è®¸å¤šç™Œç—‡æ‚£è€…ä¸­ï¼Œè¿œå¤„è½¬ç§»æ˜¯åœ¨å¤šå¹´çš„ä¼‘çœ åå‘å±•èµ·æ¥çš„ã€‚äº†è§£é€šå¸¸åœ¨å¾®è¡€ç®¡ç³»ç»Ÿé™„è¿‘å‘ç°çš„æ’­æ•£æ€§è‚¿ç˜¤ç»†èƒ ï¼ˆDTCï¼‰ å¦‚ä½•ä¿æŒä¼‘çœ çŠ¶æ€ä»¥åŠè°ƒèŠ‚å…¶é‡æ–°æ¿€æ´»çš„å› ç´ æ˜¯è‚¿ç˜¤ç”Ÿç‰©å­¦çš„ä¸»è¦æŒ‘æˆ˜ä¹‹ä¸€ã€‚åœ¨ç­›é€‰èƒ½å¤Ÿè°ƒèŠ‚è‚¿ç˜¤ç»†èƒä¼‘çœ çš„å†…çš®åˆ†æ³Œè›‹ç™½å’Œè´¨è†œè›‹ç™½æ—¶ï¼Œæˆ‘ä»¬é‰´å®šäº†è·¨è†œè›‹ç™½è¡€å°æ¿å’Œå†…çš®èšé›†å—ä½“ 1 ï¼ˆPEAR1ï¼‰ã€‚ç¼ºä¹ PEAR1 çš„äººå’Œå°é¼ å†…çš®ç»†èƒå¤±å»äº†ä¿ƒè¿›ä¸åŒè‚¿ç˜¤ç»†èƒä¼‘çœ çš„èƒ½åŠ›ï¼ŒPEAR1 çš„ç»†èƒå¤–éƒ¨åˆ†èƒ½å¤ŸæŒ½æ•‘è¿™ç§ä½œç”¨ã€‚åŒæ ·ï¼Œåœ¨å†…çš®ç»†èƒä¸­ç¼ºä¹ PEAR1 çš„å°é¼ ä¸­ï¼Œè‚ºéƒ¨è‚¿ç˜¤ç»†èƒä¼‘çœ å‡å°‘ï¼Œè‚¿ç˜¤è½¬ç§»å¢åŠ ã€‚æˆ‘ä»¬å‘ç° PEAR1 é€šè¿‡ç»“åˆèµ–æ°¨é…°æ°§åŒ–é…¶æ · 2ï¼ˆLOXL2ï¼‰å’Œç»„ç»‡è›‹ç™½é…¶ Dï¼ˆCTSDï¼‰æ¥è¯±å¯¼è‚¿ç˜¤ç»†èƒä¼‘çœ ï¼Œè¿™æ—¢èƒ½æŠ‘åˆ¶è‚¿ç˜¤ç»†èƒä¼‘çœ ï¼Œåˆèƒ½ä¿ƒè¿›è‚¿ç˜¤ç”Ÿé•¿å’Œè½¬ç§»ã€‚CTSD è¡¨è¾¾å—åˆ°æŠ‘åˆ¶çš„è‚¿ç˜¤ç»†èƒåœ¨ä½“å†…è¡¨ç°å‡ºä¼‘çœ å¢åŠ å’Œè½¬ç§»æ½œåŠ›é™ä½ã€‚æˆ‘ä»¬çš„æ•°æ®ç¡®å®šäº†è‚¿ç˜¤ç»†èƒä¼‘çœ çš„æ½œåœ¨æœºåˆ¶ï¼Œå¹¶å»ºè®®å°† CTSD å’Œ LOXL2 ä½œä¸ºä¿ƒè¿›ä¼‘çœ çš„æ–¹æ³•çš„é¶ç‚¹ã€‚<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1985427732881383424/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> <strong>æŠ—ä½“-è¯ç‰©å¶è”ç‰©åœ¨ç™Œç—‡æ²»ç–—ä¸­çš„åº”ç”¨ï¼šç°çŠ¶ã€æŒ‘æˆ˜å’Œæœªæ¥æ–¹å‘</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šç™Œç—‡<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: æŠ—ä½“-è¯ç‰©å¶è”ç‰© ï¼ˆADCï¼‰ å·²æˆä¸ºè‚¿ç˜¤å­¦ä¸­çš„ä¸€ç§å˜é©æ€§æ¨¡å¼ï¼Œå®ƒå°†æŠ—ä½“çš„é¶æ ‡ç‰¹å¼‚æ€§ä¸å¤šç§ç»†èƒæ¯’æ€§æœ‰æ•ˆè½½è·çš„é«˜æ•ˆç›¸ç»“åˆã€‚æœ¬ç»¼è¿°æä¾›äº†ä»åˆ†å­è®¾è®¡åˆ°ä¸´åºŠè½¬åŒ–çš„ ADC çš„ç»¼åˆæ¦‚è¿°ã€‚æˆ‘ä»¬å‰–æäº†ç»“æ„æˆåˆ†ã€æŠ—ä½“ã€æ¥å¤´å’Œæœ‰æ•ˆè½½è·ï¼Œå¹¶é˜æ˜äº†å®ƒä»¬å¯¹è¯ä»£åŠ¨åŠ›å­¦ã€è‚¿ç˜¤é€‰æ‹©æ€§å’Œæ²»ç–—æŒ‡æ•°çš„å½±å“ã€‚å¼ºè°ƒäº†åŒ…æ‹¬æŠ—åŸè¯†åˆ«ã€å—ä½“ä»‹å¯¼çš„å†…åŒ–ã€æœ‰æ•ˆè½½è·é‡Šæ”¾å’Œå…ç–«åŸæ€§ç»†èƒæ­»äº¡ ï¼ˆICDï¼‰ åœ¨å†…çš„æœºåˆ¶é€”å¾„ï¼Œä¸º ADC åŠŸèƒ½æä¾›èƒŒæ™¯ä¿¡æ¯ã€‚åœ¨ä¸´åºŠä¸Šï¼ŒADC å·²è¯æ˜å¯¹è¡€æ¶²ç³»ç»Ÿå’Œå®ä½“æ¶æ€§è‚¿ç˜¤å…·æœ‰ç–—æ•ˆï¼Œå·²è·å¾— 15 é¡¹ç¾å›½é£Ÿå“å’Œè¯ç‰©ç®¡ç†å±€ ï¼ˆFDAï¼‰ æ‰¹å‡†ï¼Œå¹¶ä¸æ–­æ‰©å¤§ç ”ç©¶ç®¡é“ã€‚ç„¶è€Œï¼ŒæŒ‘æˆ˜ä¾ç„¶å­˜åœ¨ï¼ŒåŒ…æ‹¬æŠ—åŸå¼‚è´¨æ€§ã€è€è¯æœºåˆ¶ã€å…¨èº«æ¯’æ€§å’Œåˆ¶é€ å¤æ‚æ€§ã€‚åŒç‰¹å¼‚æ€§ ADCã€å…ç–«åˆºæ¿€æœ‰æ•ˆè½½è·ã€äººå·¥æ™ºèƒ½å¼•å¯¼è®¾è®¡å’Œçº³ç±³æŠ€æœ¯å¢å¼ºé€’é€ç­‰æ–°å…´åˆ›æ–°æ­£åœ¨é‡å¡‘ ADC æ ¼å±€ã€‚æœ€åï¼Œæˆ‘ä»¬å¼ºè°ƒäº†è¯Šæ–­ç²¾åº¦å’Œåˆç†ç»„åˆç­–ç•¥çš„å¿…è¦æ€§ï¼ŒåŒæ—¶å¼ºè°ƒäº†å…±åŒå¡‘é€ ä¸‹ä¸€ä»£ ADC ç–—æ³•æœªæ¥æ–¹å‘çš„æ–°å…´åˆ›æ–°ã€‚<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1985427733527306240/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ“Š å­¦ç‚¹ç”Ÿä¿¡ (2æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨2æ¡ï¼‰</h4>
<p><strong>1.</strong> <strong>R Shiny ä¸­çš„è¡Œä¸ºé©±åŠ¨å¼€å‘ï¼šä½¿ç”¨ç»™å®šæ­¥éª¤è®¾ç½®æµ‹è¯•å‰ææ¡ä»¶</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šHi-Cã€histone<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šLearn how to set up test preconditions in Shiny BDD using Given steps. Master dependency injection, test doubles, and composable setup patterns for reliable R testing. Continue reading: Behavior-Driven Development in R Shiny: Setting Up Test Preconditions with Given Steps<br />
- ğŸ”— <a href="https://www.r-bloggers.com/2025/11/behavior-driven-development-in-r-shiny-setting-up-test-preconditions-with-given-steps/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> <strong>Maestro 0.7.0 å¼•å…¥äº†æ¡ä»¶ç®¡é“</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šscDNA<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šThe 0.7.0 release of maestro is out, and with it is the ability to conditionally run pipelines. In a nutshell, this is especially useful when you have DAG pipelines and you want to branch or only execute parts of a DAG when the output meets a pa... Continue reading: maestro 0.7.0 introduces conditional pipelines<br />
- ğŸ”— <a href="https://www.r-bloggers.com/2025/11/maestro-0-7-0-introduces-conditional-pipelines/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§ª åšå®¢æ›´æ–° (3æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨3æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>åˆ©ç”¨å•ç»†èƒRNAæµ‹åºè§£ç è‚¾ç™Œä¸­çš„å¹²æ‰°ç´ ä¿¡å·é€šè·¯</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€kinaseã€TCGAã€sequencingã€RNA-seqã€RNAseqã€DNA-seqã€Hi-Cã€single.cellã€single-cellã€scRNAã€scATAC<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSingle-cell RNA sequencing reveals how interferon signaling in macrophages drives resistance to immunotherapy in renal cell carcinoma, offering new insights for biomarker discovery and treatment strategies...<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/decoding-interferon-signaling-in-kidney-cancer-with-single-cell-rna-sequencing/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> â­ <strong>isoLASERé•¿è¯»é•¿RNAæµ‹åºå¯åŒºåˆ†é¡ºå¼å’Œåå¼å®šå‘çš„RNAé€‰æ‹©æ€§å‰ªæ¥</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€cardiacã€resistanceã€RNA-seqã€RNAseqã€DNA-seqã€scRNAã€scDNAã€scATAC<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šRNA sequencing using long-read technology reveals how cis- and trans-acting elements control splicing in disease-related genes including MAPT and BIN1...<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/isolaser-long-read-rna-seq-demarcates-cis-and-trans-directed-alternative-rna-splicing/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> â­ <strong>ä»å®éªŒå®¤åˆ°ç”Ÿç‰©ä¿¡æ¯å­¦ï¼šæ„å»ºä¸‹ä¸€ä»£åŸºå› æµ‹åºç½‘ç»œ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šTMEã€kinaseã€TCGAã€sequencingã€RNAseqã€bioinformaticsã€histone<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šRNA sequencing advances are empowering veterinary diagnosticians to detect emerging pathogens faster and improve animal health surveillance through hands-on training in next-generation sequencing and bioinformatics...<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/from-bench-to-bioinformatics-networking-the-next-generation-in-genetic-sequencing/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
</div>
</details>

<h2>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</h2>
<table class="keywords-table">
<thead>
<tr>
<th>å…³é”®è¯</th>
<th>å‡ºç°æ¬¡æ•°</th>
</tr>
</thead>
<tbody>
<tr>
<td>TME</td>
<td>51</td>
</tr>
<tr>
<td>scRNA</td>
<td>47</td>
</tr>
<tr>
<td>genome</td>
<td>46</td>
</tr>
<tr>
<td>scATAC</td>
<td>41</td>
</tr>
<tr>
<td>scDNA</td>
<td>39</td>
</tr>
<tr>
<td>Seurat</td>
<td>39</td>
</tr>
<tr>
<td>genomics</td>
<td>39</td>
</tr>
<tr>
<td>cancer</td>
<td>37</td>
</tr>
<tr>
<td>glioma</td>
<td>37</td>
</tr>
<tr>
<td>TCGA</td>
<td>34</td>
</tr>
<tr>
<td>histone</td>
<td>34</td>
</tr>
<tr>
<td>spatial</td>
<td>31</td>
</tr>
<tr>
<td>RNAseq</td>
<td>29</td>
</tr>
<tr>
<td>tumor</td>
<td>29</td>
</tr>
<tr>
<td>proteome</td>
<td>25</td>
</tr>
<tr>
<td>RNA-seq</td>
<td>24</td>
</tr>
<tr>
<td>single.cell</td>
<td>23</td>
</tr>
<tr>
<td>carcinoma</td>
<td>22</td>
</tr>
<tr>
<td>immune</td>
<td>22</td>
</tr>
<tr>
<td>kinase</td>
<td>20</td>
</tr>
</tbody>
</table>
<hr />
<h2>ğŸ“ æ›´å¤šå†…å®¹</h2>
<details>
<summary><a name="æ›´å¤š-å…¬ä¼—å·"></a>ğŸ“° å…¬ä¼—å· å…¶ä»–å†…å®¹ (16æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkzNzY2NDgyOQ==&amp;mid=2247493101&amp;idx=1&amp;sn=ceef86351c934a18781ac3fdc7ac937d" target="_blank" rel="noopener noreferrer">metaforåŒ…:é€‰æ‹©æ¨¡å‹ï¼ˆSelection Modelsï¼‰</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzAxMDkxODM1Ng==&amp;mid=2247546635&amp;idx=1&amp;sn=8a9fbdb461f7c704e07e61f054b3e200" target="_blank" rel="noopener noreferrer">Nature Geneticsæ‚å¿—ç‰¹åˆ«ç‰ˆå•ç»†èƒmarkeråŸºå› æ°”æ³¡å›¾</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg2NTE1MzU4NQ==&amp;mid=2247523355&amp;idx=1&amp;sn=60fbf5c6d57fa27881e17041c1eddd6f" target="_blank" rel="noopener noreferrer">10+åªéœ€è¦å…¨è½¬å½•ç»„å…³è”ç ”ç©¶TWAS+å•ç»†èƒ+æœºå™¨å­¦ä¹ ~å¿«æ¥å›´è§‚æ€è·¯å§ï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzUxMzk5MjY5NA==&amp;mid=2247649462&amp;idx=2&amp;sn=faa16e80dcf2ba783285ffb449f172d0" target="_blank" rel="noopener noreferrer">ä»å¤šç»´åˆ†æåˆ°ç©ºé—´éªŒè¯ï¼šæ„å»ºè‚¿ç˜¤å…ç–«ç ”ç©¶å®Œæ•´æ€è·¯ï¼ˆæœ‰å¥–ç›´æ’­ï¼‰</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkxMzI5MDU0Mg==&amp;mid=2247485380&amp;idx=2&amp;sn=5d41f7d3d658b0b24d2699b1654ec019" target="_blank" rel="noopener noreferrer">ä»é›¶äº†è§£ç©ºé—´è½¬å½•ç»„ç»†èƒé€šè®¯(äºŒ)</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkxMzI5MDU0Mg==&amp;mid=2247485380&amp;idx=1&amp;sn=09ae45c6c37a33a3c3ab65b1362a75cd" target="_blank" rel="noopener noreferrer">ä»é›¶äº†è§£ç©ºé—´è½¬å½•ç»„ç»†èƒé€šè®¯(ä¸€)</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg5MDk3Mzg4OA==&amp;mid=2247498404&amp;idx=1&amp;sn=d6615b113ae6d19bc0137f3cbfe0ed10" target="_blank" rel="noopener noreferrer">åˆ°ç°åœ¨è¿˜ä¸ä¼šç”¨ggforceåŒ…ï¼Ÿä¸‰åˆ†é’Ÿå¸¦ä½ ç©è½¬é«˜çº§æ•°æ®å¯è§†åŒ–ï¼Œè®©ä½ çš„å›¾è¡¨ç¬é—´é«˜å¤§ä¸Šï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkwMzY2NjkwNg==&amp;mid=2247495414&amp;idx=1&amp;sn=80a30c4ee87a6a6bb2bf379eafbb6847" target="_blank" rel="noopener noreferrer">å†¬å¤©åˆ°äº†ï¼Œç©ºè°ƒç”µè´¹çœäº†ï¼Œç»™å¤§å®¶åšç‚¹æœåŠ¡å™¨åŒ 11 æ´»åŠ¨ï¼Œä¾¿æ·å¼ç”Ÿä¿¡äº‘æœåŠ¡å™¨</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg2MDY1NTYyOQ==&amp;mid=2247498718&amp;idx=1&amp;sn=c00f20918538cdfaaabb57ba77e9334d" target="_blank" rel="noopener noreferrer">è„šæœ¬æ›´æ–°--visiumæ•°æ®çš„å¤šæ ·æœ¬å…±å®šä½ä¸åˆ†ç»„å·®å¼‚åˆ†æ</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg2NTE1MzU4NQ==&amp;mid=2247523345&amp;idx=1&amp;sn=1ce6d118f6a7e4ab54ac97307cfe6612" target="_blank" rel="noopener noreferrer">åŸºå› é€‰æ‹©ä¸å†éš¾ï¼GeneSelectRï¼šä¸€é”®å®Œæˆå¤šæ–¹æ³•ç‰¹å¾é€‰æ‹©ä¸å¯Œé›†åˆ†æ</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzU5MDcwNzg0MA==&amp;mid=2247656902&amp;idx=2&amp;sn=6598ddea37dc7c05152e76cdab17eed8" target="_blank" rel="noopener noreferrer">Cell Pressä¸æ‚¨ç›¸çº¦ç¬¬åä¸ƒå±Šå…¨å›½å…ç–«å­¦å¤§ä¼šï¼| 11æœˆ7æ—¥15ç‚¹ï¼Œç¼–è¾‘è§é¢ä¼šä¸è§ä¸æ•£</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzU5MDcwNzg0MA==&amp;mid=2247656902&amp;idx=1&amp;sn=3a82c506eebfbac401f722a170d07dd7" target="_blank" rel="noopener noreferrer">è°­è”šæ³“/å´èŠ©Cell Biomatï¼šç»ˆç»“â€œå†·è‚¿ç˜¤â€ï¼CD4+Tç»†èƒååŒæŠ‘åˆ¶ä¸‰é˜´æ€§ä¹³è…ºç™Œ | Cell Presså¯¹è¯ç§‘å­¦å®¶</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkxMzI5MDU0Mg==&amp;mid=2247485264&amp;idx=1&amp;sn=a999b3d6ee2607b76b7afed9c5b88876" target="_blank" rel="noopener noreferrer">å•ç»†èƒå¯è§†åŒ–è¿›é˜¶-Dotplot</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkxMzI5MDU0Mg==&amp;mid=2247485397&amp;idx=1&amp;sn=96ac9c8ccd37a2ec60bcd96b357ac3e0" target="_blank" rel="noopener noreferrer">å•ç»†èƒRo/e (ROE)è®¡ç®—åŠæ£’æ£’ç³–lollipopå›¾ç»˜åˆ¶</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkxMzI5MDU0Mg==&amp;mid=2247485547&amp;idx=1&amp;sn=9b354717886e2847ef4b09bc5d3ff258" target="_blank" rel="noopener noreferrer">å•ç»†èƒå¯è§†åŒ–è¿›é˜¶â€”â€”æŒ‡å®šç»†èƒç±»å‹å¯†åº¦å›¾</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkxMzI5MDU0Mg==&amp;mid=2247485587&amp;idx=1&amp;sn=49cd1249b988ac41f451204d1fef579f" target="_blank" rel="noopener noreferrer">å•ç»†èƒå¯è§†åŒ–è¿›é˜¶â€”â€”æŒ‡å®šç»†èƒç±»å‹å¯†åº¦å›¾[æ›´æ–°]</a></li>
</ul>
</div>
</details>

<details>
<summary><a name="æ›´å¤š-æ•°æ®å‰æ²¿"></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (44æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE305252" target="_blank" rel="noopener noreferrer">GSE305252 ä¹³é…°-HDAC1ä»‹å¯¼çš„è¡¨è§‚é—ä¼ é—¨æ§é€šè¿‡ä»£è°¢é‡ç¼–ç¨‹è°ƒæ§è¡€ç®¡ç”Ÿæˆè½¬å½•[ChIP-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE299661" target="_blank" rel="noopener noreferrer">GSE299661 ORB2 RNAç»“åˆè›‹ç™½é€šè¿‡å…¶åŠŸèƒ½ä¿å®ˆçš„é”Œç»“åˆâ€œZZâ€ç»“æ„åŸŸï¼Œåœ¨æœè‡æ¯ä½“å‘åˆå­è½¬å˜è¿‡ç¨‹ä¸­æŠ‘åˆ¶å…¶é¶è½¬å½•æœ¬çš„ç¿»è¯‘ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE299140" target="_blank" rel="noopener noreferrer">GSE299140 æœè‡æ¯æºå‘åˆå­è½¬å˜è¿‡ç¨‹ä¸­ï¼ŒORB2 RNAç»“åˆè›‹ç™½é€šè¿‡å…¶åŠŸèƒ½ä¿å®ˆçš„é”Œç»“åˆâ€œZZâ€ç»“æ„åŸŸæŠ‘åˆ¶é¶è½¬å½•æœ¬çš„ç¿»è¯‘ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE299109" target="_blank" rel="noopener noreferrer">GSE299109 æœè‡æ¯æºå‘åˆå­è½¬å˜è¿‡ç¨‹ä¸­ï¼ŒORB2 RNAç»“åˆè›‹ç™½é€šè¿‡å…¶åŠŸèƒ½ä¿å®ˆçš„é”Œç»“åˆâ€œZZâ€ç»“æ„åŸŸæŠ‘åˆ¶é¶è½¬å½•æœ¬çš„ç¿»è¯‘ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE305251" target="_blank" rel="noopener noreferrer">GSE305251 ä¹³é…°-HDAC1ä»‹å¯¼çš„è¡¨è§‚é—ä¼ é—¨æ§é€šè¿‡ä»£è°¢é‡ç¼–ç¨‹è°ƒæ§è¡€ç®¡ç”Ÿæˆè½¬å½•[RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293173" target="_blank" rel="noopener noreferrer">GSE293173 HIV å¯¹ Mtb/SIV å…±æ„ŸæŸ“æ’æ²³çŒ´æ¨¡å‹ä¸­æ½œä¼æ€§ç»“æ ¸æ„ŸæŸ“å½±å“çš„å•ç»†èƒè½¬å½•ç»„å­¦ç ”ç©¶ [scRNA-seq cART+3HP]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE268719" target="_blank" rel="noopener noreferrer">GSE268719 å…ˆé”‹è½¬å½•å› å­ä¹‹é—´çš„åˆ†å­å’Œä¸Šä½æ€§ç›¸äº’ä½œç”¨å¡‘é€ æ ¸å°ä½“åŠ¨åŠ›å­¦å’Œç»†èƒåˆ†åŒ–</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291137" target="_blank" rel="noopener noreferrer">GSE291137 è½¬å½•ç»„å­¦æ­ç¤ºäº†èœ±è™« Ixodes ricinus ä¸­è‚ è›‹ç™½é‡‘å±è›‹ç™½é…¶å’ŒæŠ—åŸ p23 çš„åŠŸèƒ½ä½œç”¨</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE300681" target="_blank" rel="noopener noreferrer">GSE300681 äººç±»å•æ ¸ç»†èƒè¡ç”Ÿå·¨å™¬ç»†èƒçš„ç”Ÿæˆå’Œå¤šç»„å­¦åˆ†æçš„ç®€åŒ–å’Œç»¼åˆæ–¹æ¡ˆ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293107" target="_blank" rel="noopener noreferrer">GSE293107 SKIDA1 åœ¨æ–°ç”Ÿå„¿æœŸçŸ­æš‚ç»´æŒ MLL::ENL è¡¨è¾¾çš„é€ è¡€ç¥–ç»†èƒï¼Œå¹¶ä¿ƒè¿› B ç»†èƒè°±ç³»å¯åŠ¨ [RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309745" target="_blank" rel="noopener noreferrer">GSE309745 åˆ©ç”¨å°é¼ æ¨¡å‹å’Œäººè‚ºç»„ç»‡çš„å•ç»†èƒå’Œå•æ ¸è½¬å½•ç»„åˆ†æç ”ç©¶è‚ºçº¤ç»´åŒ–</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309471" target="_blank" rel="noopener noreferrer">GSE309471 åšæ¥éœ‰ç´ è¯±å¯¼å’Œå¼ºåŠ›éœ‰ç´ è¯±å¯¼çš„TGF-Î²è½¬åŸºå› å°é¼ è‚ºçº¤ç»´åŒ–æ¨¡å‹è‚ºç»†èƒçš„å•ç»†èƒRNAæµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303777" target="_blank" rel="noopener noreferrer">GSE303777 ç—£æºæ€§é»‘ç´ ç»†èƒåŠå…¶åŒ¹é…çš„ç—…ç¶å‘¨å›´çš®è‚¤é»‘ç´ ç»†èƒçš„å•ç»†èƒRNAæµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE281161" target="_blank" rel="noopener noreferrer">GSE281161 ä¸€é¡¹ CDK9 æŠ‘åˆ¶å‰‚ voruciclib æ²»ç–—å¤å‘/éš¾æ²»æ€§æ€¥æ€§é«“ç³»ç™½è¡€ç—…å’Œ B ç»†èƒæ¶æ€§è‚¿ç˜¤çš„ 1 æœŸç ”ç©¶</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291941" target="_blank" rel="noopener noreferrer">GSE291941 ç¼ºæ°§æ¡ä»¶ä¸‹ç›˜åŸºç½‘æŸ„èŒåŸºå› è¡¨è¾¾å˜åŒ–çš„å…¨å±€ç‰¹å¾</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302849" target="_blank" rel="noopener noreferrer">GSE302849 å‰ç²’è›‹ç™½é€šè¿‡ä½œç”¨äºæ˜Ÿå½¢èƒ¶è´¨ç»†èƒä¿ƒè¿›æµ·é©¬ç¥ç»å…ƒçš„æ ‘çªç”Ÿé•¿</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302070" target="_blank" rel="noopener noreferrer">GSE302070 Treg å¯¹ç™½ç»†èƒä»‹ç´ -2 ååº”çš„å¼‚è´¨æ€§å’ŒåŒè´¨æ€§ [RNAseq2ï¼šIL2 å…ç–«ç»†èƒå› å­å¯¹å…ç–«ç»†èƒç±»å‹çš„å·®å¼‚æ€§æ¿€æ´»]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309373" target="_blank" rel="noopener noreferrer">GSE309373 æ­£å¸¸äººè‚ºç»„ç»‡ç¦»ä½“ç²¾ç¡®åˆ‡å‰²è‚ºåˆ‡ç‰‡çš„å•æ ¸RNAæµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE217257" target="_blank" rel="noopener noreferrer">GSE217257 è‘¡è„ç³–ä»£è°¢é€šè¿‡CCN1å½±å“éª¨ç»†èƒå¯¹æœºæ¢°åˆºæ¿€çš„é€‚åº”æ€§ååº”</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE277340" target="_blank" rel="noopener noreferrer">GSE277340è½¬å½•ç»„åˆ†ææ­ç¤ºäº†Hedgehogä¿¡å·é€šè·¯ä½œä¸ºç”Ÿç‰©æ ‡å¿—ç‰©åœ¨æ¢…å†…ç‰¹é‡Œå°”ç—…å‘ç—…æœºåˆ¶ä¸­çš„ä½œç”¨</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296838" target="_blank" rel="noopener noreferrer">GSE296838 å¤šè¥¿ä»–èµ›æ²»ç–—é€šè¿‡æ¿€æ´»èŠ±ç”Ÿå››çƒ¯é…¸é€šè·¯ä¸Šè°ƒä¸‰é˜´æ€§ä¹³è…ºç™Œç»†èƒä¸­é›Œæ¿€ç´ å—ä½“çš„è¡¨è¾¾</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE299316" target="_blank" rel="noopener noreferrer">GSE299316 Treg å¯¹ç™½ç»†èƒä»‹ç´ -2 ååº”çš„å¼‚è´¨æ€§å’ŒåŒè´¨æ€§ [scATAC-seq1: IL2 2h å’Œ PBS Ctl]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE268543" target="_blank" rel="noopener noreferrer">GSE268543 ä¸€é¡¹æ¯”è¾ƒè½¬å½•ç»„åˆ†æä¸ºé¦™è•‰é±¼è›‡çš„ç”Ÿæ€é€‚åº”æ€§æä¾›äº†æ–°çš„è§è§£</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE272769" target="_blank" rel="noopener noreferrer">GSE272769 å…¨è¡€è½¬å½•ç»„åˆ†æé‰´å®šå‡ºè„“æ¯’ç—‡æ­»äº¡ç‡çš„è¡¨è¾¾ç‰¹å¾</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE301342" target="_blank" rel="noopener noreferrer">GSE301342 Treg å¯¹ç™½ç»†èƒä»‹ç´ -2 ååº”çš„å¼‚è´¨æ€§å’ŒåŒè´¨æ€§ [scRNA-seq: IL2/JES6-1 æ—¶é—´åºåˆ—]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE299361" target="_blank" rel="noopener noreferrer">GSE299361 Treg å¯¹ç™½ç»†èƒä»‹ç´ -2 ååº”çš„å¼‚è´¨æ€§å’ŒåŒè´¨æ€§ [scATAC-seq2: IL2/JES6-1 æ—¶é—´è¿›ç¨‹]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE297939" target="_blank" rel="noopener noreferrer">GSE297939 ç»˜åˆ¶ ER é˜³æ€§ä¹³è…ºç™Œå¯¹å¸•åšè¥¿å°¼çš„å¤šå±‚æ¬¡åˆ†å­ååº”å›¾è°±</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE73606" target="_blank" rel="noopener noreferrer">GSE73606 ä½å‰‚é‡æŠ—é›„æ¿€ç´ ç‰©è´¨å¯¹Wistarå¤§é¼ ç¾ä¸¸çš„å½±å“[è½¬å½•ç»„åˆ†æ]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE279769" target="_blank" rel="noopener noreferrer">GSE279769 åˆ©ç”¨é…ä½“åŠŸèƒ½åŒ–çš„ CRISPR-Cas9 å¯¹å•ä¸ª G-å››é“¾ä½“è¿›è¡Œé¶å‘ï¼Œæ­ç¤ºäº†è½¬å½•ä¾èµ–æ€§åŠŸèƒ½ååº”ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292707" target="_blank" rel="noopener noreferrer">GSE292707 UGT2B17çš„éç»å…¸åŠŸèƒ½ä¿ƒè¿›å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œçš„è¿›å±•</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303687" target="_blank" rel="noopener noreferrer">GSE303687 ChAT-eGFP+è„‚è‚ªåŸºè´¨è¡€ç®¡ç»†èƒçš„å•ç»†èƒRNAæµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE217623" target="_blank" rel="noopener noreferrer">GSE217623 æ–‘é©¬é±¼é€‚ç”¨è›‹ç™½è´¨æ•°æ®åº“æ„å»ºçš„è›‹ç™½è´¨åŸºå› ç»„å­¦ç­–ç•¥æ¯”è¾ƒ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE217269" target="_blank" rel="noopener noreferrer">GSE217269 é‡ç”Ÿå‹ (WT) å’Œ Mettl3-/- (KO) BMDMï¼ˆéª¨é«“æ¥æºå·¨å™¬ç»†èƒï¼‰è½¬å½•ç»„çš„ RNA-seq åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296893" target="_blank" rel="noopener noreferrer">GSE296893 ç ”ç©¶å‘ç°ï¼Œæ¥å—æŠ—é€†è½¬å½•ç—…æ¯’æ²»ç–—çš„ HIV æ„ŸæŸ“è€…ä¸­ï¼ŒæŒç»­å­˜åœ¨çš„è‚ºç‚çƒèŒå®šæ¤ä¸é¼»è…”ç‚ç—‡ç›¸å…³ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296240" target="_blank" rel="noopener noreferrer">GSE296240 Treg å¯¹ç™½ç»†èƒä»‹ç´ -2 ååº”çš„å¼‚è´¨æ€§å’ŒåŒè´¨æ€§ [RNAseq1: IL2/JES6-1 æ—¶é—´åºåˆ—]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE306285" target="_blank" rel="noopener noreferrer">GSE306285 ä¸åŒçš„ç™½è¡€ç—…çªå˜åœ¨æ ¸ç›¸åˆ†ç¦»å‡èšä½“ä¸­æ±‡èš</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307517" target="_blank" rel="noopener noreferrer">GSE307517 ClinASOï¼šé—´éš™åä¹‰å¯¡æ ¸è‹·é…¸å¿«é€Ÿè¯ç‰©å‘ç°æŒ‡å—</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE73605" target="_blank" rel="noopener noreferrer">GSE73605 ä½å‰‚é‡æŠ—é›„æ¿€ç´ ç‰©è´¨å¯¹Wistarå¤§é¼ ç¾ä¸¸çš„å½±å“[miRNomeåˆ†æ]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292424" target="_blank" rel="noopener noreferrer">GSE292424 EGFæ¿€æ´»POMCåŸºå› è½¬å½•æ˜¯é€šè¿‡STAT3ä»‹å¯¼çš„ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE281062" target="_blank" rel="noopener noreferrer">GSE281062ç”²åŸºåŒ–èŠ¯ç‰‡ä¿¡å·æ— éœ€äºšç¡«é…¸æ°¢ç›è½¬åŒ–å³å¯é¢„æµ‹å®é™…å¹´é¾„</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE73607" target="_blank" rel="noopener noreferrer">GSE73607 ä½å‰‚é‡æŠ—é›„æ¿€ç´ ç‰©è´¨å¯¹Wistarå¤§é¼ ç¾ä¸¸çš„å½±å“</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE217338" target="_blank" rel="noopener noreferrer">GSE217338 äººç±»å¿ƒè„ç»„ç»‡å’Œäººç±»iPSCsçš„RNAæµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE297025" target="_blank" rel="noopener noreferrer">GSE297025 Tregç»†èƒå¯¹ç™½ç»†èƒä»‹ç´ -2ååº”çš„å¼‚è´¨æ€§å’ŒåŒè´¨æ€§</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287252" target="_blank" rel="noopener noreferrer">GSE287252 RNA-seq åˆ†æ WT å’Œ shTRIP6 RKO ç»†èƒä¹‹é—´å·®å¼‚è¡¨è¾¾åŸºå› ã€‚</a></li>
</ul>
</div>
</details>

<hr />
<p><em>ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2025-11-04 21:42</em><br />
<em>ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ</em></p>
    </div>
</body>
</html>